Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study

European Journal of Cancer

Volumn 50, Issue 3, 2014, Pages 611-621

  Dummer, Reinhard ^a   Goldinger, Simone M ^a   Turtschi, Christian P ^a   Eggmann, Nina B ^a   Michielin, Olivier ^b   Mitchell, Lada ^c   Veronese, Luisa ^c   Hilfiker, Paul René ^d   Felderer, Lea ^a   Rinderknecht, Jeannine D ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d MRI   (Switzerland)

Author keywords

Advanced melanoma; BRAF inhibitor; BRAF mutation; Safety; Symptomatic brain metastases; Tumour regression; Vemurafenib

Indexed keywords

B RAF KINASE; CORTICOSTEROID; VEMURAFENIB;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; COUGHING; DERMATITIS; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FEMALE; GENE MUTATION; HEMATOMA; HERPES SIMPLEX; HUMAN; HYPERKERATOSIS; ILEUS; MACULOPAPULAR RASH; MALE; METASTATIC MELANOMA; MIDDLE AGED; MULTICENTER STUDY; MUSCLE WEAKNESS; OPEN STUDY; OVERALL SURVIVAL; PAPILLOMA; PARESTHESIA; PERIPHERAL EDEMA; PILOT STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEIZURE; SKIN CARCINOMA; SKIN PAPILLOMA; SLEEP DISORDER; SOLAR DERMATITIS; SQUAMOUS CELL CARCINOMA; SWITZERLAND; THRUSH; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; YOUNG ADULT;

ADVANCED MELANOMA; BRAF INHIBITOR; BRAF MUTATION; SAFETY; SYMPTOMATIC BRAIN METASTASES; TUMOUR REGRESSION; VEMURAFENIB;

ADULT; AGED; BRAIN NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; INDOLES; MALE; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PILOT PROJECTS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84893661769     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.11.002     Document Type: Article

References (28)

1. G.T. Gibney, P.A. Forsyth, and V.K. Sondak Melanoma in the brain: biology and therapeutic options Melanoma Res 22 2012 177 183
2. J.H. Sampson, J.H. Carter Jr., A.H. Friedman, and H.F. Seigler Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma J Neurosurg 88 1998 11 20
3. J. Zakrzewski, L.N. Geraghty, and A.E. Rose et al. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival Cancer 117 2011 1711 1720
4. K.M. Fife, M.H. Colman, and G.N. Stevens et al. Determinants of outcome in melanoma patients with cerebral metastases J Clin Oncol 22 2004 1293 1300
5. T.K. Eigentler, A. Figl, and D. Krex et al. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma Cancer 117 2011 1697 1703
6. M. Staudt, K. Lasithiotakis, and U. Leiter et al. Determinants of survival in patients with brain metastases from cutaneous melanoma Br J Cancer 102 2010 1213 1218
7. S. Meier, B.G. Baumert, and T. Maier et al. Survival and prognostic factors in patients with brain metastases from malignant melanoma Onkologie 27 2004 145 149
8. M.A. Davies, P. Liu, and S. McIntyre et al. Prognostic factors for survival in melanoma patients with brain metastases Cancer 117 2011 1687 1696
9. G. Stevens, I. Firth, and A. Coates Cerebral metastases from malignant melanoma Radiother Oncol 23 1992 185 191
10. M.S. Carlino, G.B. Fogarty, and G.V. Long Treatment of melanoma brain metastases: a new paradigm Cancer J 18 2012 208 212
11. G. Bollag, P. Hirth, and J. Tsai et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Nature 467 2010 596 599
12. G.S. Falchook, G.V. Long, and R. Kurzrock et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumors: a phase 1 dose-escalation trial Lancet 379 2012 1893 1901
13. K.T. Flaherty, I. Puzanov, and K.B. Kim et al. Inhibition of mutated, activated braf in metastatic melanoma N Engl J Med 363 2010 809 819
14. G.V. Long, U. Trefzer, and M.A. Davies et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial Lancet Oncol 13 2012 1087 1095
15. V600e mutation-positive metastatic melanoma J Clin Oncol 29 2011 abstr. 8509
16. V600-mutant advanced melanoma treated with vemurafenib N Engl J Med 366 2012 707 714
17. P.B. Chapman, A. Hauschild, and C. Robert et al. Improved survival with vemurafenib in melanoma with braf v600e mutation N Engl J Med 364 2011 2507 2516
18. V600E-mutated melanoma J Clin Oncol 30 2012 abstr. 8502
19. A. Hauschild, J.J. Grob, and L.V. Demidov et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Lancet 380 2012 358 365
20. R. Dummer, J. Rinderknecht, and S. Goldinger et al. An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases J Clin Oncol 29 2011 abstr. 8548
21. R. Fisher, and J. Larkin Treatment of brain metastases in patients with melanoma Lancet Oncol 13 2012 434 435
22. K. Margolin, M.S. Ernstoff, and O. Hamid et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial Lancet Oncol 13 2012 459 465
23. U. Mahmood, Y. Kwok, W.F. Regine, and R.A. Patchell Whole-brain irradiation for patients with brain metastases: still the standard of care Lancet Oncol 11 2010 221 222
24. R. Soffietti, M. Kocher, and U.M. Abacioglu et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results J Clin Oncol 31 2013 65 72
25. E.L. Chang, J.S. Wefel, and K.R. Hess et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial Lancet Oncol 10 2009 1037 1044
26. J.P. Zacny, and S. Gutierrez Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers Psychopharmacology (Berl) 170 2003 242 254
27. J.W. Newcomer, S. Craft, T. Hershey, K. Askins, and M.E. Bardgett Glucocorticoid-induced impairment in declarative memory performance in adult humans J Neurosci 14 1994 2047 2053
28. R. Dummer, A. Hauschild, M. Guggenheim, U. Keilholz, G. Pentheroudakis ESMO Guidelines Working Group Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 23 Suppl. 7 2012 vii86 vii91